GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903).

被引：0
|
作者：
Conduit, Ciara
Mak, Blossom
Qu, Wenjia
Yeung, Theresa
Bressel, Mathias
Cusick, Thomas
Dhillon, Haryana M.
Lourenco, Richard De Abreu
Underhill, Craig
Torres, Javier
Crumbaker, Megan
Honeyball, Florian
Linton, Anthony
Sewak, Sanjeev
Chau, Nguyen Minh Hieu
Allen, Ray
Davis, Ian D.
Clark, Susan J.
Horvath, Lisa
Mahon, Kate Lynette
机构：
[1] Australian &New Zealand Urogenital & Prostate ANZ, Camperdown, NSW, Australia
[2] Chris OBrien Lifehouse, Sydney, NSW, Australia
[3] Garvan Inst Med Res, Sydney, NSW, Australia
[4] Peter Maccallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia
[5] Univ Sydney, Sch Psychol, Psycho Oncol Cooperat Res Grp,Fac Sci, Ctr Med Psychol & Evidence Based Decis Making, Sydney, NSW, Australia
[6] Univ Technol Sydney, Ctr Hlth Econ Res & Evaluat, Sydney, NSW, Australia
[7] Albury Wodonga Reg Canc Ctr, Border Med Oncol Res Unit, Albury, NSW, Australia
[8] Univ New South Wales, Rural Med Sch, Albury, NSW, Australia
[9] Goulburn Valley Hlth, Shepparton, Australia
[10] Dubbo Base Hosp, Dubbo, Australia
[11] Univ Sydney, Sydney, NSW, Australia
[12] Peninsula & South East Oncol, Frankston, Australia
[13] Latrobe Reg Hosp, Traralgon, Australia
[14] Monash Univ, Eastern Hlth Clin Sch, Box Hill, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5099
引用
收藏
页数：1
相关论文
共 50 条
  • [1] GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)
    Conduit, Ciara
    Mak, Blossom
    Qu, Wenjia
    Di Lulio, Juliana
    Burder, Ronan
    Bressel, Matthias
    Cusick, Thomas
    Dhillon, Haryana M.
    Lourenco, Richard De Abreu
    Underhill, Craig
    Torres, Javier
    Crumbaker, Megan
    Honeyball, Florian
    Linton, Anthony
    Allen, Ray
    Davis, Ian D.
    Clark, Susan J.
    Horvath, Lisa G.
    Mahon, Kate L.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [2] GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol) (vol 14, pg 1, 2022)
    Conduit, C.
    Mak, B.
    Qu, W.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [3] Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer
    de Bono, Johann S.
    Piulats, Josep M.
    Pandha, Hardev S.
    Petrylak, Daniel P.
    Saad, Fred
    Aparicio, Luis Miguel A.
    Sandhu, Shahneen K.
    Fong, Peter
    Gillessen, Silke
    Hudes, Gary R.
    Wang, Tao
    Scranton, Judith
    Pollak, Michael N.
    CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1925 - 1934
  • [4] Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
    Ning, Yang-Min
    Gulley, James L.
    Arlen, Philip M.
    Woo, Sukyung
    Steinberg, Seth M.
    Wright, John J.
    Parnes, Howard L.
    Trepel, Jane B.
    Lee, Min-Jung
    Kim, Yeong Sang
    Sun, Haihao
    Madan, Ravi A.
    Latham, Lea
    Jones, Elizabeth
    Chen, Clara C.
    Figg, William D.
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) : 2070 - 2076
  • [5] Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer
    Madan, Ravi A.
    Karzai, Fatima H.
    Ning, Yang-Min
    Adesunloye, Bamidele A.
    Huang, Xuan
    Harold, Nancy
    Couvillon, Anna
    Chun, Guinevere
    Cordes, Lisa
    Sissung, Tristan
    Beedie, Shaunna L.
    Dawson, Nancy A.
    Theoret, Marc R.
    McLeod, David G.
    Rosner, Inger
    Trepel, Jane B.
    Lee, Min-Jung
    Tomita, Yusuke
    Lee, Sunmin
    Chen, Clara
    Steinberg, Seth M.
    Arlen, Philip M.
    Gulley, James L.
    Figg, William D.
    Dahut, William L.
    BJU INTERNATIONAL, 2016, 118 (04) : 590 - 597
  • [6] Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure
    Meulenbeld, Hielke J.
    Bleuse, Jean P.
    Vinci, Elio M.
    Raymond, Eric
    Vitali, Giordano
    Santoro, Armando
    Dogliotti, Luigi
    Berardi, Rossana
    Cappuzzo, Federico
    Tagawa, Scott T.
    Sternberg, Cora N.
    Jannuzzo, Maria G.
    Mariani, Mariangela
    Petroccione, Anna
    de Wit, Ronald
    BJU INTERNATIONAL, 2013, 111 (01) : 44 - 52
  • [7] TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer
    Martin, Marc Pujalte
    Borchiellini, Delphine
    Thamphya, Brice
    Guillot, Aline
    Paoli, Jean-Baptiste
    Besson, Dominique
    Hilgers, Werner
    Priou, Frank
    El Kouri, Claude
    Hoch, Benjamin
    Deville, Jean-Laurent
    Schiappa, Renaud
    Cheli, Sandrine
    Milano, Gerard
    Tanti, Jean-Francois
    Bost, Frederic
    Ferrero, Jean-Marc
    CLINICAL GENITOURINARY CANCER, 2021, 19 (06) : 501 - 509
  • [8] Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Adesunloye, Bamidele
    Huang, Xuan
    Ning, Yangmin M.
    Madan, Ravi A.
    Gulley, James L.
    Beatson, Melony
    Kluetz, Paul Gustav
    Adelberg, David
    Arlen, Philip M.
    Parnes, Howard L.
    Mulquin, Marcia
    Steinberg, Seth M.
    Wright, John Joseph
    Trepel, Jane B.
    Dawson, Nancy Ann
    Chen, Clara
    Apolo, Andrea Borghese
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [9] A Multicentric Phase II Randomized Trial of Docetaxel Plus Enzalutamide Versus Docetaxel as First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer-CHEIRON Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 12 - 12
  • [10] Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer
    Chi, K. N.
    Hotte, S. J.
    Yu, E.
    Tu, D.
    Eigl, B.
    Tannock, I.
    Saad, F.
    North, S.
    Powers, J.
    Eisenhauer, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345